-0.42%
13.53%
11.59%
17.15%
15.88%
17.59%
49.34%
AI Spotlight on REC
Company Description
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide.The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat.It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates.
The company was founded in 1926 and is headquartered in Milan, Italy.Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Market Data
| Last Price | 58.75 |
| Change Percentage | -0.42% |
| Open | 59.2 |
| Previous Close | 59 |
| Market Cap ( Millions) | 12103 |
| Volume | 217202 |
| Year High | 59.2 |
| Year Low | 47.28 |
| M A 50 | 52.68 |
| M A 200 | 51.18 |
Financial Ratios
| FCF Yield | 3.91% |
| Dividend Yield | 2.09% |
| ROE | 23.56% |
| Debt / Equity | 1.20% |
| Net Debt / EBIDTA | -27.09% |
| Price To Book | 6.46 |
| Price Earnings Ratio | 28.64 |
| Price To FCF | 25.55 |
| Price To sales | 5.33 |
| EV / EBITDA | 15.15 |
News
- Jan -29 - 3 Companies That May Be Trading Below Their Estimated Value
- Nov -11 - Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
- Nov -08 - RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%
- Oct -09 - Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
- Oct -04 - Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
- Oct -04 - Sanofi’s rare disease drug finds yet another home
- Oct -04 - Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
- Oct -04 - RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
- Jul -18 - Italy’s Angelini Eyes Major Pharma Merger to Boost Drug Pipeline
- Jun -18 - KKR, TPG Express Interest in Italian Drugmaker Recordati
- Jun -17 - KKR, TPG Express Interest in Italian Drugmaker Recordati
- Apr -24 - CVC Explores Options for €11 Billion Drugmaker Recordati
- Apr -23 - UPDATE 1-CVC explores options for Italy's Recordati, Bloomberg News reports
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Specialty & Primary Care
Expected Growth : 5 %
What the company do ?
Recordati's Specialty & Primary Care segment focuses on developing and commercializing innovative pharmaceutical products for various therapeutic areas, including cardiovascular, women's health, and urology.
Why we expect these perspectives ?
Recordati's Specialty & Primary Care segment growth is driven by increasing demand for rare disease treatments, expansion into emerging markets, and strategic acquisitions. Additionally, investments in R&D and innovative product launches contribute to the 5% growth rate. Strong brand recognition, effective sales and marketing strategies, and a diversified product portfolio also support segment growth.
Segment n°2 -> Rare Diseases
Expected Growth : 7 %
What the company do ?
Rare Diseases from Recordati Industria Chimica e Farmaceutica S.p.A. refers to a portfolio of treatments for rare genetic disorders, including Wilson's disease and Hunter syndrome.
Why we expect these perspectives ?
Recordati's Rare Diseases segment growth is driven by increasing orphan drug demand, expansion into emerging markets, and strategic acquisitions. Growing prevalence of rare genetic disorders, advancements in gene therapy, and favorable regulatory environments also contribute to the 7% growth rate.
Recordati Industria Chimica E Farmaceutica S.P.A. Products
| Product Range | What is it ? |
|---|---|
| Cardiovascular Products | Recordati's cardiovascular products are used to treat hypertension, heart failure, and other cardiovascular diseases. |
| Women's Health Products | Recordati's women's health products are used to treat menopause symptoms, osteoporosis, and other women's health issues. |
| Specialty Care Products | Recordati's specialty care products are used to treat rare and orphan diseases, such as Fabry disease and Gaucher disease. |
| Dermatology Products | Recordati's dermatology products are used to treat skin conditions such as acne, psoriasis, and atopic dermatitis. |
| Oncology Products | Recordati's oncology products are used to treat various types of cancer, including breast, lung, and colon cancer. |
Recordati Industria Chimica e Farmaceutica S.p.A.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Recordati Industria Chimica e Farmaceutica S.p.A. is medium due to the presence of alternative products in the pharmaceutical industry.
Bargaining Power Of Customers
The bargaining power of customers for Recordati Industria Chimica e Farmaceutica S.p.A. is low due to the company's strong brand presence and customer loyalty.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Recordati Industria Chimica e Farmaceutica S.p.A. is medium due to the presence of multiple suppliers in the market.
Threat Of New Entrants
The threat of new entrants for Recordati Industria Chimica e Farmaceutica S.p.A. is high due to the increasing trend of new pharmaceutical companies entering the market.
Intensity Of Rivalry
The intensity of rivalry for Recordati Industria Chimica e Farmaceutica S.p.A. is high due to the presence of established competitors in the pharmaceutical industry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 51.37% |
| Debt Cost | 4.67% |
| Equity Weight | 48.63% |
| Equity Cost | 5.75% |
| WACC | 5.20% |
| Leverage | 105.63% |
Recordati Industria Chimica e Farmaceutica S.p.A. : Quality Control
Recordati Industria Chimica e Farmaceutica S.p.A. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| ORNAV.HE | Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
| VIRP.PA | Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Orion
A-Score
1-Year Total Return ->
🥈
Novartis
A-Score
1-Year Total Return ->
🥉
Recordati
A-Score
1-Year Total Return ->
4
Ipsen
A-Score
1-Year Total Return ->
5
GSK
A-Score
1-Year Total Return ->
6
